血栓性微血管病急诊处理实践指南
本实践指南针对血栓性微血管病(TMA)的初始管理提出四步流程:疑似诊断、综合征确认、紧急治疗和补充检查。微血管病性溶血性贫血(网织红细胞、LDH和间接胆红素升高,直接Coombs试验阴性,外周血见裂红细胞)合并非其他继发病因可解释的血小板减少,即可临床确认MAHAT。此类患者需收入重症监护室并尽快启动血浆置换,理想在最初4–8小时内开始,置换前应留取ADAMTS13和补体研究样本,同时完善病因诊断所需检查。指南认为遵循这些推荐可改善治疗结果。
要点
- MAHAT的临床确认依据:网织红细胞、LDH和间接胆红素升高,直接Coombs试验阴性,外周血见裂红细胞,并排除其他继发性病因所致的血小板减少。
- 确诊MAHAT后应收入ICU,并尽快启动血浆置换,理想在最初4–8小时内开始。
- 血浆置换开始前应留取ADAMTS13和补体研究样本。
- 应完善必要的补充检查以明确病因诊断。
- 遵循本指南推荐有助于改善TMA患者的治疗结果。
适用人群与场景
- 疑似血栓性微血管病(TMA)的急诊患者,表现为微血管病性溶血性贫血和血小板减少。
诊断标准与关键阈值
- MAHAT的综合征诊断标准:微血管病性溶血性贫血(网织红细胞升高、LDH升高、间接胆红素升高、直接Coombs试验阴性、外周血见裂红细胞)合并非其他继发性病因可解释的血小板减少。
处置流程与药物剂量
- 第一步:识别疑似TMA。
- 第二步:确认MAHAT综合征诊断。
- 第三步:收入ICU并尽快启动血浆置换,理想在最初4–8小时内开始;血浆置换前留取ADAMTS13和补体研究样本。
- 第四步:完善补充检查以明确病因诊断。
研究设计与关键结果
- 本实践指南提出TMA初始管理的四步流程:疑似诊断、综合征确认、紧急治疗和补充检查。
- 微血管病性溶血性贫血(网织红细胞、LDH和间接胆红素升高,直接Coombs试验阴性,外周血见裂红细胞)合并非其他继发性病因可解释的血小板减少,确认MAHAT综合征诊断。
- MAHAT患者需收入ICU并尽快启动血浆置换,理想在最初4–8小时内开始;置换前应留取ADAMTS13和补体研究样本。
- 应完善必要的补充检查以明确病因诊断。
证据类型、等级与局限
- 证据类型:实践指南。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对疑似TMA患者,应先确认MAHAT综合征诊断,再收入ICU并尽快启动血浆置换,理想在最初4–8小时内开始。
- 血浆置换开始前应留取ADAMTS13和补体研究样本。
- 应完善补充检查以明确病因诊断。
- 遵循本指南推荐有助于改善TMA患者的治疗结果。
指南或共识出处
- Practice guidelines for the emergency treatment of thrombotic microangiopathy(Med Clin (Barc))
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND AIM: The term thrombotic microangiopathy (TMA) involves a heterogeneous group of diseases that can be overwhelming or invalidating, with an acute development, characterised by microangiopathic haemolytic anaemia and thrombocytopaenia. Its management during its initial hours is essential to improving the prognostic of these patients. The aim of this review is to give recommendations about the optimisation of TMA initial treatment and to accelerate the aetiological diagnosis.
PATIENTS AND METHODS: We provide a practice guideline based on four steps for the initial management of TMA: diagnosis of suspicion, syndromic confirmation, emergent treatment and complementary tests.
RESULTS: The detection of microangiopathic haemolytic anaemia (characterised by elevated reticulocytes, LDH and indirect bilirubin, negative direct Coombs test and schistocytes in peripheral blood), and thrombocytopaenia not explained by other secondary aetiologies confirm the syndromic diagnosis of microangiopathic haemolytic anaemia and thrombocytopaenia (MAHAT). These patients require admission to an Intensive Care Unit to initiate plasma exchange therapy as soon as possible, ideally within the first 4-8hours. Prior to this, samples for ADAMTS13 and complement study should be obtained. Finally, it is important to request the complementary tests necessary to have a correct aetiological diagnosis.
CONCLUSIONS: Adherence to the agreed recommendations in this guideline will improve therapeutic results by facilitating cooperation between different specialists involved in TMA management.
参考来源
- Romero S, Sempere A, Gómez-Seguí I, et al. Practice guidelines for the emergency treatment of thrombotic microangiopathy. Med Clin (Barc). 2018. PMID: 29534844. doi:10.1016/j.medcli.2018.01.013
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。